Europe Sarcopenia Treatment Market - Industry Trends and Forecast to 2030
The Europe sarcopenia treatment market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing at a CAGR of 4.6% during the forecast period of 2023 to 2030.
Market SegmentationEurope Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe) - Industry Trends and Forecast to 2030
Overview of Europe Sarcopenia Treatment Market Dynamics
Drivers
• Rising prevalence of sarcopenia
Restraint
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by market players
Market Players
Some of the major market players operating in the Europe sarcopenia treatment market are:• Abbott.
• Nestlé Health Science (A subsidary of Nestlé S.A.)
• Novartis AG
• Sanofi
• Haleon Group of Companies.
• BASF SE
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• Wellona Pharma
• The Vitamin Company India
• Healing Pharma India Pvt. Ltd.
• OPKO Health, Inc.
• NMD PHARMA A/S
• Regeneron Pharmaceuticals Inc.
• Biophytis
• ARMGO Pharma, Inc.
• Rejuvenate Biomed NV.